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Abstract
Introduction: The incidence of malignant melanoma has been rising steadily over the past decades and Merkel cell carcinoma is a
highly aggressive neuroendocrine skin tumor with a high mortality rate. Sentinel lymph node (SLN) biopsy is a recommended
prognostic tool in primary cutaneous malignant melanomas of intermediate thickness and in all clinically node-negative Merkel cell
carcinomas. The gold standard method for identiﬁcation of SLNs is lymphoscintigraphy, which involves radioactive tracers.
Indocyanine green-based near-infrared ﬂuorescence imaging (NIRFI) has been also used for intraoperative SLN identiﬁcation. We aim
to evaluate the diagnostic sensitivity of the VisionSense VS3 NIRFI device for SNL identiﬁcation. This device uses stereoscopic 3D
high deﬁnition for both ﬂuorescence and visible light imaging. Our hypothesis is that SLNs may be identiﬁed transcutaneously using
ﬂuorescent dye injections and NIRFI; therefore, obviating the need for lymphoscintigraphy in the future.
Methodsandanalysis: lymph node identiﬁcation in skin malignancy using indocyanine green transcutaneously is a prospective
diagnostic sensitivity study conducted at the Department of Plastic and Hand Surgery at the University Hospital Berne, Inselspital,
Switzerland. The study aims at recruiting 93 patients (start date September 2017) to compare the accuracy of VisionSense VS3
camera at identifying SLNs transcutaneously with the current gold standard, lymphoscintigraphy. Moreover, a secondary objective is
to determine if anatomical location of the SLN and patient factors (eg, body mass index, age) have an impact on the ability of
VisionSense to detect SLNs when compared with the same gold standard.
Trial registration number: ClinicalTrials.gov NCT 03545334.
Abbreviations: BMI= bodymass index, CRF(s)= case report form(s), EDC= electronic data capturing, ICG= indocyanine green,
LN(s)= lymph node(s), LS= lymphoscintigraphy, NIRFI= near-infrared ﬂuorescence imaging, SLN(s)= sentinel lymph node(s), SLNB
(s) = sentinel lymph node biopsy(s).
Keywords: ICG, malignant melanoma, Merkel cell carcinoma, NIRFI, sentinel lymph node
1. Introduction
Switzerland has the highest incidence of melanoma in Europe
(19.2 per 100,000 per person-years).[1] Worldwide, the incidence
of malignant melanoma has been rising steadily over the past
decades, according to the World Health Organization. Compar-
ing cancer statistics from 2005 with data from 2015, the overall
incidence of malignant melanoma increased by 56.2%during this
period.[2] Malignant melanoma is less common than other skin
cancers, but at the same time has much higher mortality. The
current treatment is dependent on the histological diagnosis
following a biopsy and is determined primarily on tumor
thickness (Breslow score), the rate the cancerous cells are dividing
(mitotic rate), presence of ulceration, presence of regression, and
age of patient. Initial treatment is through surgical excision with a
safety margin of macroscopically normal skin surrounding the
tumor. If the tumor thickness is more than 1mmormore than 0.7
mm in association with high mitotic rate in younger patients,
ulceration, regression or Clark level IV/V, the current cancer
network guidelines suggest that the patient is offered a sentinel
lymph node biopsy (SLNB) as this is most likely to be the ﬁrst site
any metastasis spreads to.[3] Merkel cell carcinoma is a highly
aggressive neuroendocrine skin tumor with a mortality of
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approximately 33% at 3 years.[4] Because of the frequent
lymphatic metastasis, a SLNB is highly recommended in all the
patients to assess prognosis and guide treatment.[5]
SLNB is a staging tool for patients with clinically node-negative
primary cutaneous malignancies and no evidence of distant
metastasis. It is used to determine the histologic status of the
nodes of the regional nodal basin(s) draining the primary site. If
the sentinel lymph node (SLN) is negative, the rest of the nodes in
the basin are presumed to be negative. The status of the SLN has
been shown to be the strongest predictor of outcome in
melanoma, in patients fulﬁlling the inclusion criteria mentioned
above.[6] SLNB detects Merkel cell carcinoma in one-third of
patients whose tumors would have otherwise been clinically and
radiologically under-staged and who may not have received
treatment to the involved node bed. There is a signiﬁcant beneﬁt
of adjuvant nodal therapy, but only when the SLNB is positive.
Therefore, SLNB is important for both prognosis and treatment
of Merkel cell carcinoma patients.[7]
The current gold standard technique to identify SLNs is to
inject the radioisotope Technetium 99 m intra-dermally around
the location of the primary tumor.[8] The patient is then scanned
while the radiotracer gives off energy in the form of gamma rays.
The detection of these rays through a special camera gives then
the location of the SLN at approximately 30 and 120 minutes.
However, many surgeons favor the combination of radiocolloid
with a blue dye to have 2 methods of identifying the SLN.[9]
However, there are concerns regarding the use of radioactive
agents not only for the patients, but also for the medical staff.[10]
Indocyanine green (ICG) is a green dye reagent already used for
hepatic function and cardiac output function.[11] It can be used
with near-infrared ﬂuorescence imaging (NIRFI), having an
absorption peak of 800 nm.[12] The real-time ﬂuorescence
navigation with ICG for the identiﬁcation of SLN in patients with
malignant melanoma was ﬁrst used in 2009.[13] In the following
years, this technique has been further researched and various
publications are available on this subject.[14,15] Even though
other teams have tried to transcutaneously (“before skin
incision”) identify SLNs with ICG and NIRFI, they concluded
that ICG ﬂuorescence technique is not reliable in patients with a
high body mass index (BMI) or in patients with a primary tumor-
draining in the axillary node ﬁeld, and therefore a prior
identiﬁcation of the location of the SLN would be necessary
with lymphoscintigraphy (LS). The SLN could; however, be
easily identiﬁed “after skin incision” with a precision of
98.9%.[16] Most papers cite a depth of 0.5 to 2cm of the ICG
that could be seen with the available NIRFI devices.[17]
Nevertheless, the current literature lacks clinical trials investigat-
ing the use of ICG and NIRFI in skin malignancies.
This study aims to evaluate a medical device that uses
improved technology compared to previous studies: VisionSense
VS3 (rumed GmbH, Lostorf, Switzerland). This device uses
stereoscopic 3D high deﬁnition for both ﬂuorescence and visible
light imaging. Our hope is that by applying similar principles,
SLNs may be identiﬁed transcutaneously using ﬂuorescent dye
injections and NIRFI; therefore, obviating the need for LS in the
future.
2.1. Study objectives and diagnostic approaches
The primary objective of the lymph node identiﬁcation in skin
malignancy using indocyanine green transcutaneously (LIMIT)
study is to investigate the diagnostic sensitivity of VisionSense
VS3 NIRFI to transcutaneously identify SLNs in melanomas and
Merkel cell carcinomas as effectively as LS, which is considered
the current gold standard. The secondary objective is to
determine if anatomical location of SLN and patient factors
(eg, BMI, sex, age, etc) have an effect on the ability of VisionSense
VS3 NIRFI to detect SLNs when compared with the same gold
standard, LS.
2.2. Trial design and study setting
The LIMIT study is designed as a single-blinded, single-center,
single-arm, not randomized diagnostic sensitivity study. The
center in which the study is conducted is the Department of
Plastic and Hand Surgery, University Hospital Berne, Inselspital
(single-centre). The single-arm description refers to the fact that
our study does not contain comparisons between different
patients or interventions (no randomization). Since the surgeon
will be blinded with regards to the number of lymph nodes (LNs)
detected by the LS until after performing the procedure with ICG
and NIRFI, the term “single-blinded” can be used to describe our
study. The estimated study duration is 2 years and each patient
will be assessed by both diagnostic approaches.
2. Methods and analysis
2.3. Guidelines and ethical conduct of study
The study will be carried out in accordance to the protocol and
with principles enunciated in the current version of the
Declaration of Helsinki, the guidelines of good clinical practice
and the Swiss regulatory authorities’ requirements. We also
designed our study in accordance with the “Standards for
Reporting Diagnostic Accuracy Studies”.[18]
2.4. Patient population and eligibility criteria
Individuals fulﬁlling all of the following inclusion criteria are
eligible for the study:
 Informed consent as documented by signature
 Patient must present with any of the following cancer types:
^Malignant melanoma with one of the following character-
istics:
(1) Breslow score ≥1 mm
(2) Breslow score ≥0.7mm associated with ulceration
(3) Breslow score ≥0.7mm associated with regression
(4) Breslow score ≥0.7mm associated with Clark Level IV/V
(5) Breslow score ≥0.7mm associated with mitotic rate ≥1/
mm2 in young patients
^Merkel cell carcinoma
The presence of any one of the following exclusion criteria will
lead to exclusion of the individual:
 Age <18 years
 Pregnancy and breastfeeding (pregnancy test to be performed
for women of child-bearing potential, deﬁned as women who
are not surgically sterilized/hysterectomized, and/or who are
postmenopausal for less than 12 months)
 Known allergy to ICG or iodine
 Previous chemotherapy, radiotherapy, or surgery to the LNs of
interest
 Lack of capacity to provide informed consent
 Current enrolment in any other interventional study
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2.5. Recruitment and consent
Patients who fulﬁll the inclusion criteria for the study will be sent
an information packet detailing the background rationale of the
study and the details of the surgical procedure. Before surgery a
member of the study group will conﬁrm the patient’s willingness
to participate in the study. If they agree, they will be formally
consented regarding procedures, risks, and beneﬁts of the study.
2.6. Criteria for withdrawal/discontinuation of participants
The participants are withdrawn from the study if they withdraw
their consent, if the operation cannot take place anymore for
medical reasons, if they are proven to have distant metastases
following radiological staging or if there are no LNs on LS.
2.7. Outcome measures
Sensitivity on the number of LNs identiﬁed will be used as
primary and secondary outcome measure.
The primary end-point is represented by the analysis of the case
report forms (CRFs) collected after the surgeries: once the
responsible surgeon has either identiﬁed or failed to identify a
SLN transcutaneously, he/she is unblinded and the CRF is
completed according to the comparisons made to the LS ﬁndings.
Secondary outcomes will be analyzed once the study period is
completed. Data relating to the ability of SLNs to be successfully
identiﬁed transcutaneously will be grouped anatomically or
according to patient characteristics such as BMI, sex, and age and
statistically analyzed to determine if certain anatomical regions or
patient groups have different sensitivity rates.
Any patient who chooses to terminate the study early will
receive the same postoperative (standard) care and follow-up as
those included in the study.
2.8. Statistical analysis and sample size calculation
The statistical analysis will be performed by a statistician at the
end of the study (ie, when all patients are included). Baseline
characteristics will be reported asmean and standard deviation or
median and interquartile range, and number and percentage of
patients for continuous and categorical variables, respectively.
The sensitivity (ie, the proportion of NIRFI and LS positive LN
among LS positive LN) will be reported with a 95% conﬁdence
interval (CI) and adjusted for multiple observations per patients
using generalized estimating equations[19] or the method by Rao
and Scott.[20] The number of LS-negative LNs that are NIRFI
positive will be reported.
Data relating to the ability of SLNs to be successfully identiﬁed
transcutaneously by NIRFI will be grouped anatomically and
according to patients’ characteristics (eg, BMI, sex, and age) and
afterward analyzed to determine if certain anatomical regions or
patient groups have different sensitivity rates.
Only patients with positively identiﬁed LNs in LS will be
included in the study and there will be no missing data from the
LS. We do not expect any or only a small number of missing
NIRFI data. However, patients with missing data in NIRFI will
be excluded from the main analysis. For a sensitivity analysis, we
will assume that all missing NIRFI results will be negative. The
number of missing data will be reported together with the reasons
behind their absence.
All of the patients will have at least 1 positive LN in LS, but
there could also be cases with more than 1 LN per patient,
increasing the precision of the sensitivity estimate. As it is not
possible to make a reasonable assumption about the number of
LNs per patient and the correlations of the measurements within
a patient, we will recruit 93 patients. Sample size at the required
absolute precision level for sensitivity was calculated with
Buderer formula.[19,20] We assumed a sensitivity of 60% (based
on Namikawa et al – identiﬁcation rate with ICG of 63.4%
before skin incision[16]) and a maximum clinically acceptable
width of the 95% CI of 10% (ie, 50%–70%), for a total of 93
LNs identiﬁed by LS.
2.9. Timeline
At the beginning of the study, all involved personnel are
introduced in their tasks. All the patients undergoing SLNB are
checked to ensure they fulﬁll the inclusion/exclusion criteria of
the trial. A patient information pack is sent to home address
detailing the study and aims of the clinical trial. Figure 1 depicts
the exact outline of a patient included in our study, including
deviations from the standard. On admission, 1 day before the
scheduled operation, a preoperative consultation explaining the
surgical procedure including the risks and beneﬁts of surgery
takes place and the patient is consented for both the surgical
procedure and for participation in the study. On the day of
surgery, the patient attends a nuclear medicine appointment for
the LS on the morning of the planned surgery. This will be
performed in accordance with the standardized technique of
injecting 4 small volumes (0.1–0.4 mL) of Technicium99 around
the site of the primary tumor. The patient will then have scans
taken at approximately 30 and 120 minutes following injection
to locate the SLN(s), but he/she will not have the location of the
SLN marked on his or her skin with permanent marker. The
patient will be asked not to disclose the location of the detected
SLN to the surgeon or any other member of the surgical team to
ensure that the surgeon is blinded to the result and limit the degree
of bias in the study.
After the patient is anaesthetized under full general anesthetic,
the responsible surgeon will inject 0.2 to 0.4 mL of ICG
intradermally around the site of the primary tumor. The surgeon
will wait for a period of 5 to 15 minutes to allow for ICG to be
absorbed and passed into the lymphatic system, and afterward,
the VisionSense VS3 HD3D camera will be used to attempt to
locate the SLN after conﬁrming the camera is functioning
correctly by commencing the scan at the site of ICG injection. The
scan will proceed depending on the site of the primary tumor,
with investigation of the presumed draining LNs. The identiﬁed
LNs will be marked with a red marker and the locations
documented in the CRF. Afterward, the nuclear medicine
department will be telephoned and asked to upload the scans
and radiology report of the LS onto the electronic system. The
surgeon will visualize the location of the LS scan and locate them
on the patient using a gamma probe using a blue permanent skin
marker. The surgeon will ONLY perform the SLN biopsy on the
LNs identiﬁed by LS. Any LNs identiﬁed by the VisionSense VS3
HD3D camera which do not correlate with the LS results will
NOT be biopsied. The operation will be carried out in accordance
with the standard operative procedure using a combined
approach of gamma probe navigation and ﬂuorescent imaging.
Once the patient has been re-admitted to the ward the
responsible surgeon will make a routine postoperative visit of the
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patient and the surgical wounds will be inspected for any early
operative complications. The patientwill be informed of the surgical
procedure and ﬁndings, including the results of the clinical trial. Any
adverse events will be recorded in the CRF. A second postoperative
consultation will take place on the day following surgery and the
surgical wounds will be inspected again. Once the patient has
fulﬁlled standard discharge criteria they will be prepared for
discharge. A prescription for analgesia will be provided.
LIMIT study - paen reatment protocol
Minutes in item
Deviaon 
from
standard
Intervenon
Pre-
operave 
day - 01
Informaon about the study 
and the paent's consent to 
parcipate in the study
Clariﬁcaon for anesthesia
Laboratory tests, if 
required by the 
anaesthest
Imaging tumor 
diagnoscs, if necessary
none
none
Day of
surgery
Appointment at Nuclear
medicine
Surgery
Tecnicium99 Injecon
for Lymphoscingraphy
No marking 
on the 
paent
Paent is
anaesthesed
Intradermale ICG 
Injecon
Examinaon with the
VisionSense Kamera
Lymph-
node iden-
ﬁcaon with
the
VisionSense
HD3D
Surgeon is unblinded 
by the outcome of the 
LS
Comparison of the ICG 
marking with the LS and 
documentaon of the 
data
 
camera
Performance of the 
operaon
Sennel Lymphknoten-
Biopsy
Recovery from anaesthesia
P t i b ht b k t th
None
None
None
POD 01
a ent s roug  ac  o e 
ward
Postoperave visit Assessment of the 
wound.
Communicate the resultPaent is discharged home
None
POD 14
   
of the operaon
   
outpaent appointment
Assessment of the 
wound.
Communicate 
histological result
None
Figure 1. Timeline of a patient included in the study, including deviations from the standard.
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2.10. Data management and collection
The CRFs in this trial are implemented electronically using a
dedicated electronic data capturing (EDC) system (REDCap).
The EDC system is activated for the trial only after successfully
passing a formal test procedure. All data entered in the CRFs are
stored on a Linux server in a dedicated mySQL database.
Responsibility for hosting the EDC system and the database
lies with the clinical trial unit Bern.
All data entered into the CRFs are transferred to the database
using secure sockets layer encryption. Each data point has
attributes attached to it identifying the user who entered it with
the exact time and date. Retrospective alterations of data in the
database are recorded in an audit table. Time, table, data ﬁeld
and altered value, and the person are recorded (audit trail).
A multi-level back-up system is implemented. Back-ups of the
whole system including the database are run internally several
times per day and on external tapes once a day. The back-up
tapes are stored in a secure place in a different building.
2.11. Data monitoring and auditing
For quality control of the study conduct and data retrieval, the
study site will be visited on-site by an appropriately trained and
qualiﬁed monitor. Any ﬁndings and comments will be docu-
mented in site visit reports and communicated to the investigator
and the sponsor as applicable. The investigator will support the
monitor in his/her activities. Before the study start (ﬁrst
participant enrolled) a plan detailing all monitoring-related
procedures will be developed.
All source data and relevant documents will be accessible to
monitors and questions of monitors are answered during site
visits.
Since this is a single-center investigator-initiated trial, the
sponsor does not plan to perform any audits. If the competent
authority (Swissmedic) or competent ethics committee performs
an inspection on-site, staff will support the inspectors in their
activities, study documentation, and the source data/source
documents will be accessible to inspectors and study staff will
answer questions from inspectors as needed. All involved parties
must keep the participant data strictly conﬁdential.
The number and type of adverse effects will be listed and
reported. Also, any deviation will be communicated to the data
monitoring committee and to the research team in a joint
meeting.
An interim analysis will be performed after 60 examined
patients to analyze how many LNs could be successfully
identiﬁed transcutaneously by NIRFI until then and if there is
a signiﬁcant difference in the number of identiﬁed LNs with the
standard methods.
2.12. Data protection: data access and conﬁdentiality
Direct access to source documents will be permitted for purposes
of monitoring and inspections. The investigator ensures
anonymity of the patients; patients will not be identiﬁed by
names in any documents leaving the study site. Signed informed
consent forms and patient enrolment log will be kept strictly
conﬁdential to enable patient identiﬁcation at the site.
Each LN is identiﬁed by a unique consecutive patient- LN
identiﬁcation number. A list with the identiﬁcation numbers will
be kept in the investigator site ﬁle at the study site, with access
restricted to study personnel only.
2.13. Ethics and dissemination
The trial is registered in the ClinicalTrials.gov online trial
database (NCT 03545334). The results of the trial will be
published in subject matter related peer-reviewed scientiﬁc
journals with a signiﬁcant impact on the medical scientiﬁc
community. The results of the trial will also be presented at the
meetings of Swiss and international societies of Plastic Surgery
and Dermatology. Since the use of the medical device is according
to its intention there are no trade secret issues involved. Protocol
modiﬁcations will require a formal amendment to the protocol
which will be reported to the Competent Ethics Committee for
approval.
2.14. Patient and public involvement
No patient involved.
3. Discussion
While the intraoperative detection rate of SLNs with ICG and
NIRFI is 100%, the preoperative, transcutaneous identiﬁcation
rates have values of 23.8% in the axillary region and around
85% in the head and neck and groin area.[16] Due to these low
rates, the preoperative identiﬁcation would still have to rely on
the gold standard technique, the LS. However, the use of this
technology is not without disadvantages: the use of radioactive
agents is harmful not only for the patient, but also for the surgeon
and staff.[10]
The medical device used in our study is the Visionsense VS3 –
stereoscopic high deﬁnition visualization system. Its use is based
on ICG ﬂuorescence visualization transcutaneously with the
device-speciﬁc infrared ﬂuorescence visualization system. While
other studies found the identiﬁcation of SLNs “before skin
incision” unreliable, we hope that the new technology with high
deﬁnition infrared ﬂuorescence scope and high deﬁnition 3D
camera, as well as laser light source used to generate the
ﬂuorescence excitation illumination, will allow us to conﬁrm our
hypothesis and reduce/obviate the need for LS in the future in the
future.
Because of the unpredictability of the number of patients,
patient recruitment may be delayed and; therefore, the study
period may not be adhered. Even though our sample size
calculation might be underestimated, with some of the patients
having more than 1 SLN, we believe that having more than 93
LNs will only increase our precision of the sensitivity estimate.
With our work, we hope to establish a new gold standard for
the identiﬁcation of SLN in cases of malignant melanoma and
Merkel cell carcinoma. If our hypothesis proves true, we will be
able to offer the patients a different technique for SLN
identiﬁcation, without the need for radioactive tracers; therefore,
avoiding the risks associated with radiation.
3.1. Strengths and limitations of this study
This study aims at validating a new device for identiﬁcation of
SLNs to avoid in the future the use of radioactive tracers and their
potential adverse effects for a common diagnostic procedure. The
study will provide clear-cut data determining the safety and study
design for randomized comparative studies between LS and
NIRFI for SLN biopsies. A limitation of our study is the
impossibility of determining speciﬁcity as the event of a false
negative ﬁnding in LS is not possible
Lese et al. Medicine (2019) 98:44 www.md-journal.com
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3.2. Trial status
The trial is currently actively recruiting patients. Completion of
patient recruitment is expected for the beginning of 2020.
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